Zydus Lifesciences Ltd

- There is no explicit mention of any current or future fundraising through debt or equity in the provided pages of the document. - The discussion primarily focuses on operational performance, R&D spend, product launches, market expansion, litigation, tax rates, and strategic initiatives. - No statements or guidance related to raising capital via debt or equity were noted.

- The company is commissioning a new facility as part of a joint venture (JV) related to Perfect Day, aimed at setting up a Contract Development and Manufacturing Organization (CDMO) facility. (Page 8, 9) - The wellness business acquisition, including RiteBite Max Protein, is about INR 130 crores in annual revenue and focuses on healthy snacking and nutrition space. (Page 8) - The company is investing in building end-to-end infrastructure and capabilities to be a long-term player in the US animal health space. (Page 13) - A significant part of R&D spending—around 8% of revenue—is sustained for developing complex generics, biologics, NCEs, and US clinical development, including a large Phase III trial. (Page 21) - The company continues to focus on innovation and portfolio expansion with multiple new launches and pipeline developments planned in FY27 and FY28. (Page 19, 21)

- India business aims to grow better than market with focus on innovative and growth booster brands driving sustained growth. - Emerging markets expected strong double-digit revenue and faster profitability growth, leveraging global product portfolio and new markets (UK, Australia, Canada). - US business to grow in FY26 over FY25 despite competition (Asacol), with major launches planned in FY27 and FY28 offering large opportunities. - Mirabegron is expected to continue growing quarter on quarter and remains a major product in FY26. - FY26 to see meaningful opportunities from Sitagliptin 505(b)(2), injectables, and internal pipeline products. - R&D spend sustained around 8% of revenue to support portfolio expansion and innovation for long-term growth. - Overall, the company is on track to achieve aspirational growth and profitability for FY25 and beyond with a strong product pipeline.

- FY26 US business is expected to grow over FY25 despite competition (e.g., Asacol). - FY27 and FY28 anticipated to be significantly larger due to assured Day 1 exclusive product launches. - Mirabegron remains a growing product quarter-on-quarter, contributing to sustained growth. - Overall, the company is on track to achieve aspirational growth and profitability for FY25. - EBITDA margin guidance for FY25 remains at around 27%, with expectations for 100-150 bps improvement over the previous year. - India branded formulations business targets better-than-market growth, supported by a growing chronic portfolio (now >41% of domestic business). - Emerging markets are expected to continue strong double-digit revenue and profitability growth despite challenges. - R&D spend planned at ~8% of revenue, supporting innovation and future product launches. - No new upward or downward revision to FY25 estimates; current guidance remains valid.

- The transcript does not explicitly mention exact figures or details about the current or expected orderbook/pending orders. - There is a mention of tenders expected to last 2-3 years, indicating potential sizeable opportunities. Competition is limited to 1-3 players, suggesting a good chance of meaningful wins. - On the US side, the company has a strong pipeline with upcoming product launches, including exclusive Day 1 launches expected in FY27 and FY28, signaling a growing portfolio and order potential. - The company is also building capabilities for new product commercialization like gadolinium MRI injectables. - Overall, Zydus Lifesciences is optimistic about future business growth driven by new launches, portfolio reorganization, and specialty/chronic portfolio expansion, which underpins expected demand and orders.